The company is seeking conditional marketing authorisation (CMA) for patients with DMD who are not using glucocorticoids.
News
New molecular diagnostics business launched in Manchester
The aim of APIS Assay Technologies is to help to realise the clinical and commercial potential of genomic medicine in diagnostic tests and personalisation of treatment.
Zolgensma wins FDA green light in child SMA
The $2.1 milllion per treatment price tag has garnered substantial criticism.
Final NICE guidance issued for Akcea’s Tegsedi
The drug should be available for routine use within 90 days for patients in England.
GSK updates its sales rep incentives
The company implemented stricter rules in 2012 as part of a broad transparency initiative.
NHS to undergo ‘ambitious’ tech overhaul
In the past three months alone, the NHS has prevented more than 21 million potential cyber attacks.
AZ’ HER2 drug hits mid-stage trial endpoints
The drug has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation.
LifeArc receives $1.2b in Keytruda royalties
In 2016, LifeArc sold a small proportion of its Keytruda royalty interest for $150 million to a private equity fund.
CMA accuses four pharmas of anticompetitive behaviour
Four pharma companies stand accused in the UK of colluding to artificially inflate the price of prescription-only, anti-nausea and dizziness drug prochlorperazine, costing the NHS millions of pounds and breaking competition law.
Scancell, CR UK publish joint vaccine update
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Vulnerable children stuck in mental health hospitals for too long
Too many children are being admitted to secure hospitals unnecessarily, and in some cases are spending months and years of their childhood in institutions.
New data highlights value of Janssen’s Spravato
The approval of the drug is a new way of treating adults with TRD that is unlike other treatment options in psychiatry.
Insilico, ARK initiate health-span and longevity partnership
The newly developed ‘ARK’ will develop a programme of events to facilitate networking in AI research across King’s.
KCL findings could improve STI vaccines
Researchers have shown how skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues.
Nintedanib hits targets in rare lung disease trial
The drug was successful in patients with systemic sclerosis associated interstitial lung disease.
